Lymphoma with central nervous system involvement in a young patient with crohn disease treated with azathioprine

Journal of Pediatric Gastroenterology and Nutrition

Volumn 51, Issue 6, 2010, Pages 790-792

  Loganathan, S S ^a   Zaitoun, A ^a   Charlton, C P J ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CARMUSTINE; CYTARABINE; ETOPOSIDE; GLYCOPROTEIN; MELPHALAN; MESALAZINE; STEROID; TOPIRAMATE;

ABDOMINAL PAIN; ABDOMINAL RADIOGRAPHY; ADOLESCENT; ARTICLE; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; DIARRHEA; DRUG DOSE INCREASE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; HUMAN TISSUE; ILIAC CREST; LAPAROTOMY; LARGE CELL LYMPHOMA; PRIORITY JOURNAL; RECURRENT DISEASE; ULCER; ULTRASOUND; WEIGHT REDUCTION;

ADOLESCENT; AZATHIOPRINE; BRAIN NEOPLASMS; CROHN DISEASE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINE, SMALL; LYMPHOMA;

EID: 78650517230     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e3181edf33f     Document Type: Article

References (29)

1. Fraser AG, Orchard TR, Robinson EM, et al. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther 2002;16:1225-32.
2. Farrell RJ, Ang Y, Kileen P, et al. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut 2000;47:514-9.
3. Korelitz BI, Mirsky FJ, Fleisher MR, et al. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine. Am J Gastroenterol 1999;94:3248-53.
4. Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: Benefits outweigh the risk of lymphoma. Gastroenterology 2000;118:1018-24.
5. Sanderson IR, Kingston JE, Khan S, et al. Hodgkin's disease complicating Crohn's disease in a child. J R Soc Med 1985;78:860-1.
6. Present DS, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: Short- and long-term toxicity. Ann Intern Med 1989;111:641-9.
7. Lewis JD, Bilker WB, Brensinger C, et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001;121:1080-7.
8. Palli D, Trallori G, Bagnoli S, et al. Hodgkin's disease risk is increased in patients with ulcerative colitis. Gastroenterology 2000; 119:647-53.
9. Jess T, Winther KV, Munkholm P, et al. Intestinal and extra-intestinal cancer in Crohn's disease: Follow-up of a population-based cohort in Copenhagen County, Denmark. Aliment Pharmacol Ther 2004;19:287-93.
10. Karlén P, Löfberg R, Brostrom O, et al. Increased risk of cancer in ulcerative colitis: A population-based cohort study. Am J Gastroenterol 1999;94:1047-52.
11. Ekbom A, Helmick C, Zack M, et al. Extracolonic malignancies in inflammatory bowel disease. Cancer 1991;67:2015-9.
12. Loftus EV Jr, Tremaine WJ, Habermann TM, et al. Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol 2000;95:2308-12.
13. Opelz G, Döhler B. Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004;4:222-30.
14. Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 1985;78:44-9.
15. Kinlen LJ, Sheil AG, Peto J, et al. Collaborative United Kingdom- Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med J 1979;2:1461-6.
16. Connell WR, Kamm MA, Dickson M, et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994;343:1249-52.
17. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005;54:1121-5.
18. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: A prospective observational cohort study. Lancet 2009;374:1617-25.
19. Armstrong RG, West J, Card TR. Risk of cancer in inflammatory bowel disease treated with azathioprine: A UK population-based case-control study. Am J Gastroenterol 2010;105:1604-9.
20. Nalesnik MA, Jaffe R, Starzl TE, et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 1988;133:173-92.
21. Holmes RD, Sokol RJ. Epstein-Barr virus and post-transplant lymphoproliferative disease. Pediatr Transplant 2002;6:456-64.
22. Stevens SJ, Verschuuren EA, Pronk I, et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001;97:1165-71.
23. Kumar S, Fend F, Quintanilla-Martinez L, et al. Epstein-Barr viruspositive primary gastrointestinal Hodgkin's disease: Association with inflammatory bowel disease and immunosuppression. Am J Surg Pathol 2000;24:66-73.
24. Calaminici MR, Sheaff MT, Norton AJ, et al. Ileocaecal Epstein-Barr virus-positive lymphoproliferative disorder complicating Crohn's disease. Histopathology 1999;35:388-90.
25. Li S, Borowitz MJ. Primary Epstein-Barr virus-associated Hodgkin disease of the ileum complicating Crohn disease. Arch Pathol Lab Med 2001;125:424-7.
26. Losco A, Gianelli U, Cassani B, et al. Epstein-Barr virus-associated lymphoma in Crohn's disease. Inflamm Bowel Dis 2004;10:425-9.
27. Van Biervliet S, Velde SV, De Bruyne R, et al. Epstein-Barr virus related lymphoma in inflammatory bowel disease. Acta Gastroenterol Belg 2008;71:33-5.
28. Larvol L, Soule JC, Le Tourneau A. Reversible lymphoma in the setting of azathioprine therapy for Crohn's disease. N Engl J Med 1994; 331:883-4.
29. Dayharsh GA, Loftus EV Jr, Sandborn WJ, et al. Epstein-Barr viruspositive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 2002; 122: 72-7.